Position in NVAX
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$2,231,682
+$1,943,860 QoQ
Shares Held
236,909
+570.0% QoQ
Ownership
0.144%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#42
of 263 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVAX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Quantinno Capital Management LP holds $570,630,052 across 169 Biotechnology names. NVAX ranks #45 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
163,085 | $81,009,212 | |
| 2 | JAZZ |
Jazz Pharmaceuticals plc
|
273,506 | $65,906,740 | |
| 3 | TECH |
BIO-TECHNE Corp
|
502,361 | $35,491,804 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
47,009 | $29,311,991 | |
| 5 | RPRX |
Royalty Pharma plc
|
470,482 | $26,379,925 | |
| 6 | INCY |
Incyte Corp
|
214,446 | $24,309,598 | |
| 7 | ROIV |
Roivant Sciences Ltd.
|
546,694 | $19,347,500 | |
| 8 | MRNA |
Moderna, Inc.
|
219,606 | $15,379,008 |
All Filings in NVAX
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,231,682 | 236,909 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $287,822 | 35,359 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $154,929 | 23,055 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $229,468 | 26,467 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $110,867 | 17,598 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||